OXCIA AB
Desconocido
TOPFIBRO: Targeting OGG1 in Idiopathic Pulmonary Fibrosis
OXCIA AB
tramitó un
HORIZON EUROPE:
HORIZON-EIC-2022-TRANSITION-01
Idiopathic Pulmonary Fibrosis (IPF) is a progressive lung disease with no curative therapies. Approved therapies for IPF have a high rate of...
2023-03-16 - 2026-04-30 | Financiado
2023-03-16 - 2026-04-30 | Financiado
CODIC: COmmercializing first in class dCTPase Inhibitors for treatment of hematological Cancers
OXCIA AB
participó en un
H2020:
ERC-2015-PoC
In our ERC grant GEnetic NEtworks as a tool for anti-CAncer Drug Development we used siRNA screening and genetic
networks to identify dCTPas...
2015-12-22 - 2017-06-30 | Financiado
2015-12-22 - 2017-06-30 | Financiado
* No se disponen de datos de la empresa actual.